Gilead Sciences -- Physician Payments Report
This page provides a comprehensive analysis of Gilead Sciences's payments to physicians, as reported in the CMS Open Payments (Sunshine Act) database. DoctorPharmaData enhances this data with AI-powered analysis to help patients understand pharmaceutical company spending patterns.
Spending Summary
Gilead Sciences has made $9,993,684.09 in total payments to 0 physicians across 773 recorded transactions.
- Total Physician Spending: $9,993,684.09
- Total Physicians Paid: 0
- Total Payment Transactions: 773
Recent Payment Records
The following table shows the most recent payments from Gilead Sciences to physicians as recorded in the CMS Open Payments database.
| Doctor | Specialty | Amount | Type | Date |
|---|---|---|---|---|
| Nicole Lopez | Infectious Disease | $64.58 | meals | 2026-04-09 |
| Christopher Clark | Hepatology | $2,346.47 | general | 2026-04-05 |
| Mark Perez | Pulmonology | $220.65 | meals | 2026-04-02 |
| Christine Edwards | HIV Medicine | $218.80 | meals | 2026-04-01 |
| Sarah Chen | Infectious Disease | $30,961.39 | consulting | 2026-03-31 |
| Michael Rodriguez | Hepatology | $5,391.55 | consulting | 2026-03-31 |
| Steven Green | Infectious Disease | $1,761.57 | general | 2026-03-28 |
| Amy Phillips | Pulmonology | $3,319.32 | consulting | 2026-03-28 |
| Benjamin Cook | HIV Medicine | $77.03 | general | 2026-03-28 |
| Lisa Garcia | Pulmonology | $1,276.50 | general | 2026-03-28 |
| Timothy Rogers | Hepatology | $96.94 | meals | 2026-03-26 |
| Ashley Nelson | Infectious Disease | $2,982.36 | general | 2026-03-26 |
| Michelle Scott | Hepatology | $91,354.98 | research | 2026-03-26 |
| Angela Stewart | Oncology | $20,136.99 | consulting | 2026-03-25 |
| Melissa Reed | HIV Medicine | $1,477.93 | general | 2026-03-24 |
Understanding Pharmaceutical Company Payment Reports
Under the Physician Payments Sunshine Act, pharmaceutical and medical device companies must report all payments and transfers of value to licensed physicians and teaching hospitals. Gilead Sciences is required to disclose every payment, including consulting fees, speaking engagements, meals, travel, research funding, and ownership interests.
A high spending total does not necessarily indicate improper behavior. Large pharmaceutical companies with extensive product portfolios naturally make more payments to physicians. However, examining the patterns of spending -- which specialties are targeted, which doctors receive the most, and what types of payments predominate -- can provide valuable insights for patients.
Related Resources
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice.